Download PDF
Endoscopy 2003; 35(2): 112-117
DOI: 10.1055/s-2003-37013
State of the Art Review
© Georg Thieme Verlag Stuttgart · New York

Reflux Disease and Barrett’s Esophagus

S.  Haag1 , G.  Holtmann1
  • 1Dept. of Gastroenterology and Hepatology, Institute of Internal Medicine, University of Essen, Essen, Germany
Further Information

Publication History

Publication Date:
30 January 2003 (online)

Also available at
    Permissions and Reprints

Gastroesophageal reflux disease (GERD) is one of the most prevalent gastrointestinal disorders. The key feature of GERD is reflux of gastric contents into the esophagus. Medical treatment with proton-pump inhibitors (PPIs) is well established and is considered the standard treatment. Given the high prevalence of the condition and the excellent response to medical therapy, antireflux surgery is an option for patients with volume reflux that is not properly controlled by medical therapy. Adenocarcinoma is a rare but life-threatening complication of GERD. The only known precursor lesion for esophageal adenocarcinoma is Barrett's esophagus. In recent years, a clearer understanding of the development of Barrett's and of its progression toward invasive cancer has developed. Genetic factors almost certainly determine the individual risk. The length of the Barrett's esophagus segment and the size of a hiatal hernia are associated with the risk of developing high-grade dysplasia and esophageal adenocarcinoma.
With regard to the clinical management of GERD patients with Barrett's, endoscopic surveillance at 3-year intervals is now considered appropriate in the absence of dysplasia. In patients with high-grade dyspepsia, the situation is more difficult. While a considerable proportion of these patients may already have invasive cancers, there is also the possibility that there is only focal dysplasia. For this reason, it is justifiable to carry out curative endoscopic resection. Mucosal ablation procedures may also be appropriate, but these still need to be properly investigated in clinical trials.

References

  • 1 Bollschweiler E, Wolfgarten E, Gutschow C, Holscher A H. Demographic variations in the rising incidence of esophageal adenocarcinoma in white males.  Cancer. 2001;  92 549-555
    CrossrefPubMedGoogle Scholar
  • 2 Avidan B, Sonnenberg A, Giblovich H, Sontag S J. Reflux symptoms are associated with psychiatric disease.  Aliment Pharmacol Ther. 2001;  15 1907-1912
    CrossrefPubMedGoogle Scholar
  • 3 Colombo P, Mangano M, Bianchi P A, Penagini R. Effect of calories and fat on postprandial gastro-oesophageal reflux.  Scand J Gastroenterol. 2002;  37 3-5
    CrossrefPubMedGoogle Scholar
  • 4 Romero Y, Cameron A J, Schaid D J. et al . Barrett’s esophagus: prevalence in symptomatic relatives.  Am J Gastroenterol. 2002;  97 1127-1132
    CrossrefPubMedGoogle Scholar
  • 5 Fackler W K, Ours T M, Vaezi M F, Richter J E. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough.  Gastroenterology. 2002;  122 625-632
    PubMedGoogle Scholar
  • 6 Richter J E. H. pylori: the bug is not all bad.  Gut. 2001;  49 319-320
    PubMedGoogle Scholar
  • 7 Koike T, Ohara S, Sekine H. et al . Increased gastric acid secretion after Helicobacter pylori eradication may be a factor for developing reflux oesophagitis.  Aliment Pharmacol Ther. 2001;  15 813-820
    PubMedGoogle Scholar
  • 8 Moayyedi P, Bardhan C, Young L. et al . Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease.  Gastroenterology. 2001;  121 1120-1126
    CrossrefPubMedGoogle Scholar
  • 9 Sonnenberg A. What to do about Helicobacter pylori? A decision analysis of its implication on public health.  Helicobacter. 2002;  7 60-66
    CrossrefPubMedGoogle Scholar
  • 10 Wu J C, Chan F K, Wong S K. et al . Effect of Helicobacter pylori eradication on oesophageal acid exposure in patients with reflux oesophagitis.  Aliment Pharmacol Ther. 2002;  16 545-552
    CrossrefPubMedGoogle Scholar
  • 11 Hurenkamp G J, Grundmeijer H G, van der EA . et al . Arrest of chronic acid suppressant drug use after successful Helicobacter pylori eradication in patients with peptic ulcer disease: a six-month follow-up study.  Aliment Pharmacol Ther. 2001;  15 1047-1054
    CrossrefPubMedGoogle Scholar
  • 12 Goldblum J R, Richter J E, Vaezi M. et al . Helicobacter pylori infection, not gastroesophageal reflux, is the major cause of inflammation and intestinal metaplasia of gastric cardiac mucosa.  Am J Gastroenterol. 2002;  97 302-311
    CrossrefPubMedGoogle Scholar
  • 13 Castell D O, Vela M. Combined multichannel intraluminal impedance and pH-metry: an evolving technique to measure type and proximal extent of gastroesophageal reflux.  Am J Med. 2001;  111 (Suppl 8A) 157S-159S
    PubMedGoogle Scholar
  • 14 Edwards S J, Lind T, Lundell L. Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis.  Aliment Pharmacol Ther. 2001;  15 1729-1736
    PubMedGoogle Scholar
  • 15 Zhang Q, Lehmann A, Rigda R. et al . Control of transient lower oesophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in patients with gastro-oesophageal reflux disease.  Gut. 2002;  50 19-24
    CrossrefPubMedGoogle Scholar
  • 16 Katz P O. Lessons learned from intragastric pH monitoring.  J Clin Gastroenterol. 2001;  33 107-113
    CrossrefPubMedGoogle Scholar
  • 17 Lundell L, Miettinen P, Myrvold H E. et al . Continued (5-year) follow-up of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease.  J Am Coll Surg. 2001;  192 172-179
    CrossrefPubMedGoogle Scholar
  • 18 Frazzoni M, Grisendi A, Lanzani A. et al . Laparoscopic fundoplication versus lansoprazole for gastro-oesophageal reflux disease: a pH-metric comparison.  Dig Liver Dis. 2002;  34 99-104
    CrossrefPubMedGoogle Scholar
  • 19 Spechler S J, Lee E, Ahnen D. et al . Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial.  JAMA. 2001;  285 2331-2338
    CrossrefPubMedGoogle Scholar
  • 20 Mason R J, Hughes M, Lehman G A. et al . Endoscopic augmentation of the cardia with a biocompatible injectable polymer (Enteryx) in a porcine model.  Surg Endosc. 2002;  16 386-391
    PubMedGoogle Scholar
  • 21 Sampliner R E. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett’s esophagus.  Am J Gastroenterol. 2002;  97 1888-1895
    CrossrefPubMedGoogle Scholar
  • 22 Souza R F, Morales C P, Spechler S J. A conceptual approach to understanding the molecular mechanisms of cancer development in Barrett’s oesophagus.  Aliment Pharmacol Ther. 2001;  15 1087-1100
    CrossrefPubMedGoogle Scholar
  • 23 Dixon M F, Neville P M, Mapstone N P. et al . Bile reflux gastritis and Barrett’s oesophagus: further evidence of a role for duodenogastro-oesophageal reflux?.  Gut. 2001;  49 359-363
    CrossrefPubMedGoogle Scholar
  • 24 Tharalson E F, Martinez S D, Garewal H S. et al . Relationship between rate of change in acid exposure along the esophagus and length of Barrett’s epithelium.  Am J Gastroenterol. 2002;  97 851-856
    CrossrefPubMedGoogle Scholar
  • 25 Zentilin P, Conio M, Mele M R. et al . Comparison of the main oesophageal pathophysiological characteristics between short- and long-segment Barrett’s oesophagus.  Aliment Pharmacol Ther. 2002;  16 893-898
    CrossrefPubMedGoogle Scholar
  • 26 Avidan B, Sonnenberg A, Schnell T G. et al . Hiatal hernia size, Barrett’s length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma.  Am J Gastroenterol. 2002;  97 1930-1936
    CrossrefPubMedGoogle Scholar
  • 27 Geddert H, Heep H J, Gabbert H E, Sarbia M. Expression of cyclin B1 in the metaplasia-dysplasia-carcinoma sequence of Barrett esophagus.  Cancer. 2002;  94 212-218
    CrossrefPubMedGoogle Scholar
  • 28 Shen B, Ormsby A H, Shen C. et al . Cytokeratin expression patterns in noncardia, intestinal metaplasia-associated gastric adenocarcinoma: implication for the evaluation of intestinal metaplasia and tumors at the esophagogastric junction.  Cancer. 2002;  94 820-831
    CrossrefPubMedGoogle Scholar
  • 29 Going J J, Keith W N, Neilson L. et al . Aberrant expression of minichromosome maintenance proteins 2 and 5, and Ki-67 in dysplastic squamous oesophageal epithelium and Barrett’s mucosa.  Gut. 2002;  50 373-377
    CrossrefPubMedGoogle Scholar
  • 30 Rabinovitch P S, Longton G, Blount P L. et al . Predictors of progression in Barrett’s esophagus, 3: baseline flow cytometric variables.  Am J Gastroenterol. 2001;  96 3071-3083
    CrossrefPubMedGoogle Scholar
  • 31 Rader A E, Faigel D O, Ditomasso J. et al . Cytological screening for Barrett’s esophagus using a prototype flexible mesh catheter.  Dig Dis Sci. 2001;  46 2681-2686
    CrossrefPubMedGoogle Scholar
  • 32 Scotiniotis I A, Kochman M L, Lewis J D. et al . Accuracy of EUS in the evaluation of Barrett’s esophagus and high-grade dysplasia or intramucosal carcinoma.  Gastrointest Endosc. 2001;  54 689-696
    CrossrefPubMedGoogle Scholar
  • 33 Sonnenberg A, Soni A, Sampliner R E. Medical decision analysis of endoscopic surveillance of Barrett’s oesophagus to prevent oesophageal adenocarcinoma.  Aliment Pharmacol Ther. 2002;  16 41-50
    CrossrefPubMedGoogle Scholar
  • 34 Buttar N S, Wang K K, Anderson M A. et al . The effect of selective cyclooxygenase-2 inhibition in Barrett’s esophagus epithelium: an in vitro study.  J Natl Cancer Inst. 2002;  94 422-429
    PubMedGoogle Scholar
  • 35 Buttar N S, Wang K K, Leontovich O. et al . Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett’s esophagus.  Gastroenterology. 2002;  122 1101-1112
    CrossrefPubMedGoogle Scholar
  • 36 Buskens C J, van Rees B P, Sivula A. et al . Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus.  Gastroenterology. 2002;  122 1800-1807
    PubMedGoogle Scholar
  • 37 Sampliner R E, Camargo L, Fass R. Impact of esophageal acid exposure on the endoscopic reversal of Barrett’s esophagus.  Am J Gastroenterol. 2002;  97 270-272
    CrossrefPubMedGoogle Scholar
  • 38 Carlson N, Lechago J, Richter J. et al . Acid suppression therapy may not alter malignant progression in Barrett’s metaplasia showing p53 protein accumulation.  Am J Gastroenterol. 2002;  97 1340-1345
    CrossrefPubMedGoogle Scholar
  • 39 Javaid B, Watt P, Krasner N. Photodynamic therapy (PDT) for oesophageal dysplasia and early carcinoma with mTHPC (m-tetrahydroxyphenyl chlorin): a preliminary study.  Lasers Med Sci. 2002;  17 51-56
    CrossrefPubMedGoogle Scholar
  • 40 Buttar N S, Wang K K, Lutzke L S. et al . Combined endoscopic mucosal resection and photodynamic therapy for esophageal neoplasia within Barrett’s esophagus.  Gastrointest Endosc. 2001;  54 682-688
    PubMedGoogle Scholar

G. Holtmann, M.D.

Universitätsklinikum Essen · Medizinische Klinik und Poliklinik · Abteilung für Gastroenterologie

Hufelandstrasse 55 · 45122 Essen

Fax: + 49-201-723-5970 ·

Email: g.holtmann@uni-essen.de

      >